Solid Biosciences (SLDB) Revenue (2021 - 2022)
Solid Biosciences (SLDB) posted Revenue of $6.2 million for Q2 2022, up 220.47% sequentially from $1.9 million in Q1 2022, and up 71.65% YoY from $3.6 million in Q2 2021.
Powered by 
Analysis
Solid Biosciences (SLDB) Revenue (2021 - 2022) Analysis & Trends
Solid Biosciences has reported Revenue for 2 years, with the latest figure at $6.2 million in Q2 2022.
- Quarterly Revenue rose 71.65% year-over-year to $6.2 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $6.2 million (down 49.48% YoY) and the FY2022 annual result came in at $8.1 million, down 40.57% from the prior year.
- Revenue improved to $6.2 million in Q2 2022 per SLDB's latest filing, from $1.9 million in the prior quarter.
- Over five years, Revenue peaked at $6.2 million in Q2 2022 and troughed at $1.9 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Solid Biosciences | 1.49 Bn | 1.49 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 6.17 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 3.15 Mn |
| Sep 30, 2021 | 3.54 Mn |
| Jun 30, 2021 | 3.59 Mn |
| Mar 31, 2021 | 3.34 Mn |